Can tigecycline inhibit gram positive bacteria effectively?

Can tigecycline stop gram-positive bacteria from growing?

Tigecycline blocks protein synthesis in bacteria by binding to the 30S ribosomal subunit. It covers most gram-positive species, including MRSA, vancomycin-resistant enterococci, and penicillin-resistant pneumococci. Laboratory tests show it stops growth at low concentrations against these organisms.

Does it work against methicillin-resistant staphylococci?

Yes. Tigecycline keeps activity against methicillin-resistant S. aureus (MRSA) and methicillin-resistant S. coagulase-negative staphylococci. Clinical isolates in surveillance programs show susceptibility rates above 95 percent.

What about enterococci that resist vancomycin?

Tigecycline also covers vancomycin-resistant enterococci (VRE). No cross-resistance occurs with glycopeptides, therefore it remains reliable against VRE isolates.

How does tigecycline compare with other antibiotics for gram-positive infections?

Tigecycline shows similar or better activity than linezolid or daptomycin in vitro against many drug-resistant gram-positive bacteria. In clinical trials it reached non-inferiority versus vancomycin for complicated skin infections and versus imipenem for intra-abdominal infections. Non-inferiority was also reported in hospital-acquired pneumonia studies.

What side effects do patients report?

Nausea and vomiting occur in more than 20 percent of patients. Higher rates of all-cause mortality appeared in some pooled analyses, prompting FDA warnings. The agent is approved only for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia.

When does the patent expire?

Tigecycline's composition-of-matter patent expired in 2011. Generic versions entered the market after 2015. DrugPatentWatch.com lists current generic manufacturers and ongoing litigation over formulation patents.